Florida Atlantic Tests a Lung Cancer Quantum Classifier on D-Wave Hardware: 91.90% on an Advantage Processor and 94.31% in Simulation, Discover Quantum Science, 9 September 2026
How Florida Atlantic ran a lung cancer quantum support vector machine on D-Wave hardware
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
Engineers at Florida Atlantic University have taken their quantum classifiers off the simulator and onto a working quantum computer. In a study that predicts lung cancer from symptoms and risk factors, a quantum support vector machine running on a D-Wave Advantage processor classified 91.90 percent of test cases correctly, against 94.31 percent for the same method in simulation.
The paper, by Muhammad Minoar Hossain, Md. Hasibul Hassan Himal and Arslan Munir, appeared in Discover Quantum Science on 9 September 2026 as article 34 of volume 2. The university announced it on 2 November 2026 in a Florida Atlantic release that calls the findings preliminary. The study asks a narrow question about lung cancer prediction: how quantum learning methods behave when the training set is kept deliberately small.
For a hospital reader, the step worth noting is the hardware. In August Quentir reported that the same group's 90.26 percent heart-disease result came from a simulator. This time the team ran its highest-scoring model on D-Wave annealing hardware, on two D-Wave systems, and reported the hardware numbers next to the simulated ones.
The starting point is a public file, the Lung Cancer Dataset posted on Kaggle by Mysar Ahmad Bhat in 2023. It holds 309 entries with 15 input attributes, such as smoking, yellow fingers, wheezing, coughing and chest pain, and a yes-or-no lung cancer label. It contains no medical images, pathology results, laboratory values or cancer stages. The authors describe their work as "a preliminary screening-support and methodological study rather than a clinical diagnostic system."
The cancer and non-cancer groups in the file were unequal in size, so the team applied SMOTE, a technique introduced by Chawla and colleagues in the Journal of Artificial Intelligence Research in 2002 that creates synthetic examples by interpolating between real neighbors in the smaller class. That brought the file to 540 entries, 270 per class. A feature-selection step written as a QUBO, the binary optimization format that quantum annealers solve, then kept ten inputs: allergy, alcohol consumption, wheezing, swallowing difficulty, coughing, chest pain, peer pressure, yellow fingers, chronic disease and smoking.
The evaluation turns the usual split around. The 540 entries were divided into five partitions of 108. In each of five rounds the models trained on one partition and were tested on the remaining 432. Training on one fifth of the data is deliberate: it imitates the small cohorts that many hospital and rare-disease datasets offer.
The team compared three classifiers: quantum support vector machines, quantum k-nearest neighbors and quantum boosting. Gate-based versions ran through IBM's Qiskit, Google's Cirq and Xanadu's PennyLane, and annealing versions ran through OpenJij and D-Wave's Ocean software. Testing every method under one data preparation and one evaluation protocol is the paper's main methodological contribution, since many quantum machine learning papers test one method on one platform.
The D-Wave quantum support vector machine scored highest, at 94.31 percent in simulation. On hardware it reached 91.90 percent on the system D-Wave calls Advantage_system6 and 90.05 percent on Advantage_system4. The paper describes Advantage_system6 as a sixth-generation Advantage2 processor with the Zephyr topology. D-Wave's own solver documentation lists both systems as Advantage processors with the Pegasus topology and reserves the Advantage2 and Zephyr labels for solvers named Advantage2_system, so this post follows the manufacturer. D-Wave's hybrid solvers landed between 87.04 and 91.89 percent. The gate-based quantum k-nearest neighbors method reached 92.96 percent in Qiskit and 92.99 percent in PennyLane, so the top hardware result sits below two gate-based simulations in the same paper.
The gate-based side ran into a practical limit. When the team tried the Qiskit quantum support vector machine on an IBM quantum computer, the job called for 59,719,680 circuit shots, above IBM's system limit of 10,000,000. The authors cut that hardware test down to 50 samples, 30 for training and 20 for testing. Quantum kernel methods compare every pair of training examples, so their cost grows quickly with the size of the dataset, and that growth is a fair question for any vendor offering such a model.
Shionogi Wins NEDO's ¥40 Million Quantum Computing Prize for Drug Design: What the Scientific Reports Study With D-Wave's Annealer Shows
What Shionogi won in Japan's NEDO quantum computing contest, and what its annealing study shows
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
Shionogi, the Osaka drug maker, took first place and a ¥40 million prize in the Quality of Life category of the NEDO Challenge on quantum computing, Japan's state-funded contest for quantum solutions to social problems. D-Wave Quantum announced the win on 28 October 2026 and tied it to a peer-reviewed study in which its quantum annealing hardware helped a generative AI model design drug-like molecules.
The study is the part a medicinal chemist can check. Published open access in Scientific Reports on 9 July 2026, Table 1 of the published article reports that 96.97 percent of the molecules generated with the annealer's help were chemically valid, against 61.95 percent for the same model with a classical sampler. The quantum-assisted model also produced a larger share of compounds with high drug-likeness scores than its training set contained, while repeating itself more often.
Those are computed scores on a public chemistry dataset. The study reports no synthesis and no biological testing of any generated molecule, and the prize money is meant to fund the next steps of that research.
NEDO, the New Energy and Industrial Technology Development Organization that operates under Japan's Ministry of Economy, Trade and Industry, held the award ceremony in Tokyo on 15 October 2026 and posted the official list of winners the following day. The contest ran in three areas: Society 5.0, Quality of Life and Cool Japan. First prize in each area carries ¥40 million, second ¥20 million and third ¥10 million. First place in Society 5.0 and Cool Japan was left vacant, which makes Shionogi the only first-place winner this season.
NEDO's list describes Shionogi's entry in Japanese as solving drug discovery problems through two complementary uses of quantum computers: generating the structures of candidate compounds, and evaluating the interaction energy between molecules. The other Quality of Life prizes went to two teams working on the gut and wider microbiome: Mori-san Daisuki Club in second place with a quantum search method for designing gut bacterial communities, and Q4Health in third place for microbiome design aimed at next-generation antimicrobial treatments.
The D-Wave study maps onto the first of Shionogi's two tracks. Quantum Computing Report wrote on 23 October 2026 that all nine general prize winners used IBM Quantum hardware, and it described Shionogi's entry as a quantum and high-performance computing hybrid that evaluates binding energy and generates structures through a method called Deep QSCI. D-Wave's announcement says the award covered Shionogi's broader research, including, among other achievements, the annealing study. A reader should therefore treat the prize as recognition for a two-part program run on more than one kind of quantum machine.
QTomo Says Quantum Computing Can Rebuild CT Scans From 10 Percent of the X-Ray Data: What Kyungtaek Jun's Papers From 2023 to 2026 Tested
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
A Korean start-up called QTomo says its quantum algorithms can rebuild a CT scan from one tenth of the usual X-ray projections, which would cut a patient's radiation dose by 90 percent. The company's founder, Kyungtaek Jun, made those claims in a newspaper interview published on 24 September 2026, and his own peer-reviewed papers show how far the method has actually been tested.
Jun has published the core of QTomo's approach in Scientific Reports in 2023 and 2025, in two arXiv preprints in April and May 2025 and in EPJ Quantum Technology in July 2026. The experiments in those papers perform quantum CT reconstruction on images of at most 100 by 100 pixels, solve the problem on the D-Wave hybrid solver, which combines a quantum annealer with classical computing, and use test objects such as the Shepp-Logan phantom, a standard computer-drawn head outline, a model tooth or a single existing chest CT slice. The 90 percent figure appears as an estimate in the April 2025 preprint, and none of the papers reports a scan acquired from a patient for the study, a dose measurement or a clinical validation.
That gap matters for radiology departments and hospital buyers, because the interview lists early cancer detection, breast and heart imaging and dental work among the technology's proposed clinical applications. The published papers describe a careful and interesting research program at a much earlier stage.
Set side by side, the interview's figures and the papers' measurements separate into three groups: claims with peer-reviewed support on small test images, one estimate from a preprint, and figures that appear in no paper at all. The first group shows steady progress by a small research team. The second would need a scanner study to confirm it, and the third would need data that QTomo has not yet made public.